干细胞、冲击波与富血小板血浆治疗勃起功能障碍和佩罗尼病:美国诊所调查
该研究通过标准化电话调查美国79家提供干细胞、富血小板血浆(PRP)或冲击波疗法的诊所,了解其费用、人员配置和疗效数据。结果显示这些标签外疗法广泛使用,但缺乏科学数据支持其对患者的宣称,作者认为需要更多监管和标准化。
要点
- 79家诊所中93.7%回答了部分问题,多数同时治疗勃起功能障碍和佩罗尼病。
- 每次注射平均费用:干细胞5291美元,PRP 1336美元;每次冲击波治疗413美元。
- 67%的治疗有医生参与,仅6家诊所报告有泌尿外科医生参与。
核心结论
- 数据表明干细胞、PRP和冲击波等标签外疗法在美国广泛用于勃起功能障碍和佩罗尼病,但缺乏科学数据支持向患者所做的宣称。
- 作者认为需要对这些新型再生疗法进行更多监管和标准化。
研究设计与样本
- 通过在线网站目录系统检索美国不同地区的诊所,采用一系列标准化问题询问治疗费用、疗程时长、参与的医务人员和患者结局数据。
- 共调查26家干细胞治疗诊所、26家PRP治疗诊所和27家冲击波治疗诊所,合计79家。
主要发现
- 79家被联系诊所中93.7%对问题提供了部分回答,多数同时提供勃起功能障碍和佩罗尼病治疗。
- 每次干细胞注射平均费用5291美元,每次PRP注射平均费用1336美元,每次冲击波治疗平均费用413美元。
- 67%的治疗有医生参与,79家诊所中仅6家报告有泌尿外科医生参与。
- 超过75%的诊所报告患者治疗后满意。
- 据诊所报告,疗效持续时间从数月到数年不等。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify clinics offering off-label therapies for erectile dysfunction (ED) and Peyronie's disease (Pyd) including stem cell, platelet-rich plasma (PRP), and shockwave therapy and to determine the transparency they provided to patients inquiring about these treatment modalities. METHODS: Clinics were identified in different regions in the US using a systematic search on online website directories and were approached by asking a series of standardized questions regarding the cost of treatment, duration of therapy, the medical staff involved, and patient outcome data. A total of 26 clinics were surveyed for stem cell therapy, 26 for PRP treatment, and 27 for shockwave therapy. RESULTS: Of the 79 clinics contacted, 93.7% provided some answers to the questions we asked, with a majority offering treatments for both ED and Pyd. The cost of treatment varied widely between clinics. The average cost per stem cell therapy injection was $5291, PRP per injection was $1336, and shockwave therapy per session was $413. A physician was involved in 67% of treatments, and only 6 of 79 clinics reported that a urologist was involved. Over 75% of the clinics reported patient satisfaction following treatment. Durability of benefits to patients ranged from months to years according to the clinics' reports. CONCLUSION: Our data not only demonstrate the widespread use of off-label therapies for ED and PyD across the United States but also the lack of scientific data to support the claims made to patients. This study highlights the need for more oversight and standardization in novel regenerative therapies for ED and PyD.
引用
- Thomas J, Sencaj M, Ghomeshi A, et al. Stem-Cell, Shockwave, and Platelet Rich Plasma Therapy for the Treatment of Erectile Dysfunction and Peyronie's Disease: A Survey of Clinics Across the USA. Urology. 2023. PMID: 37076023. doi:10.1016/j.urology.2023.01.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。